Other · developed by Oculis
Licaminlimab is an investigational eye drop given three times daily for 29 days in a trial in dry eye disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07548632 | Phase 2/3 | Dry Eye Disease (DED) | Active not recruiting | OCS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dry Eye Disease (DED)
Updated Oct 25, 2026. Something wrong or missing? Report it on the OCS page.
See OCS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OCS catalysts and pipeline →